HomeCompareCLBS vs O

CLBS vs O: Dividend Comparison 2026

CLBS yields 131.33% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.96M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CLBS vs O

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, CLBS beats the other by $4,417,119.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + O for your $10,000?

CLBS: 50%O: 50%
100% O50/50100% CLBS
Portfolio after 10yr
$6.51M
Annual income
$2,603,408.21/yr
Blended yield
39.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
O buys
0
No recent congressional trades found for CLBS or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSO
Forward yield131.33%5.28%
Annual dividend / share$0.56$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$12.99M$34.2K
Annual income after 10y$5,201,713.69$5,102.74
Total dividends collected$11.90M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CLBS vs O ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrO PortfolioO Income/yrGap
1← crossover$23,833$13,133.21$10,818$608.16+$13.0KCLBS
2$54,754$29,252.94$11,787$741.68+$43.0KCLBS
3$121,396$62,809.15$12,946$911.00+$108.5KCLBS
4$260,039$130,144.39$14,345$1,127.94+$245.7KCLBS
5$538,781$260,539.45$16,056$1,409.05+$522.7KCLBS
6$1,080,999$504,503.28$18,171$1,777.83+$1.06MCLBS
7$2,102,673$946,004.75$20,820$2,268.21+$2.08MCLBS
8$3,969,574$1,719,713.85$24,188$2,929.90+$3.95MCLBS
9$7,281,647$3,034,202.37$28,533$3,837.11+$7.25MCLBS
10$12,993,076$5,201,713.69$34,235$5,102.74+$12.96MCLBS

CLBS vs O: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CLBS vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs KOCLBS vs MAINCLBS vs STAGCLBS vs ADCCLBS vs NNNCLBS vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.